Efficacy, Safety and Pharmacokinetics of IL-17 Monoclonal Antibody Injection (AK111) in Patients with Moderate-to-Severe Plaque Psoriasis: A Randomized, Double-Blinded, Placebo-Controlled Phase Ib Multidose Escalation Clinical Study

被引：0

作者：

Congjun Jiang

Huan Zhou

Wanlu Zhang

Yu Xia

Baiyong Li

Xiang Ni

Guoqin Wang

Wenhui Zhang

Benchao Chen

Zhimei He

Min Zhang

Rui Chen

Hongzhong Jin

Liehua Deng

机构：

[1] The First Affiliated Hospital of Jinan University and Jinan University Institute of Dermatology,Department of Dermatology

[2] The First Affiliated Hospital of Bengbu Medical College,Department of Dermatology

[3] The First Affiliated Hospital of Bengbu Medical College,National Institute of Clinical Drug Trials

[4] Akeso Biopharma,Clinical Pharmacology Research Center, Peking Union Medical College Hospital, State Key Laboratory of Complex Severe and Rare Diseases, NMPA Key Laboratory for Clinical Research and Evaluation of Drug, Beijing Key Laboratory of Clinical PK

[5] Inc.,Department of Dermatology, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital

[6] Chinese Academy of Medical Sciences and Peking Union Medical College,undefined

[7] Chinese Academy of Medical Science and Peking Union Medical College,undefined

[8] National Clinical Research Center for Dermatologic and Immunologic Disease,undefined

来源：

Dermatology and Therapy | 2023年 / 13卷

关键词：

AK111; Interleukin-17; Safety; Phase Ib; Psoriasis;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：555 / 567

页数：12

共 50 条

[1] Efficacy, Safety and Pharmacokinetics of IL-17 Monoclonal Antibody Injection (AK111) in Patients with Moderate-to-Severe Plaque Psoriasis: A Randomized, Double-Blinded, Placebo-Controlled Phase Ib Multidose Escalation Clinical Study
Jiang, Congjun
Zhou, Huan
Zhang, Wanlu
Xia, Yu
Li, Baiyong
Ni, Xiang
Wang, Guoqin
Zhang, Wenhui
Chen, Benchao
He, Zhimei
Zhang, Min
Chen, Rui
Jin, Hongzhong
Deng, Liehua
DERMATOLOGY AND THERAPY, 2023, 13 (02) : 555 - 567
[2] Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis
Ryan, C.
Menter, A.
Guenther, L.
Blauvelt, A.
Bissonnette, R.
Meeuwis, K.
Sullivan, J.
Cather, J. C.
Yosipovitch, G.
Gottlieb, A. B.
Merola, J. F.
Duffin, K. Callis
Fretzin, S.
Osuntokun, O. O.
Burge, R.
Naegeli, A. N.
Yang, F. E.
Lin, C. -Y.
Todd, K.
Bleakman, A. Potts
BRITISH JOURNAL OF DERMATOLOGY, 2018, 179 (04) : 844 - 852
[3] Bimekizumab efficacy and safety in Korean patients with moderate to severe plaque psoriasis: A phase 3, randomized, placebo-controlled, double-blinded study
Youn, Sang Woong
Jo, Seong Jin
Park, Chul Jong
Kim, Dong Hyun
Shin, Bong Seok
Jeong, Ki Heon
Bang, Chul Hwan
Cross, Nancy
Thirlwell, Jackie
Hoepken, Bengt
JOURNAL OF DERMATOLOGY, 2024, 51 (11): : 1392 - 1403
[4] Population pharmacokinetic/pharmacodynamic analysis of AK111, an IL-17A monoclonal antibody, in subjects with moderate-to-severe plaque psoriasis
Li, Qian
Qiao, Ju
Jin, Hongzhong
Chen, Benchao
He, Zhimei
Wang, Guoqin
Ni, Xiang
Wang, Max
Xia, Michelle
Li, Baiyong
Chen, Rui
Hu, Pei
FRONTIERS IN PHARMACOLOGY, 2022, 13
[5] A multicenter, randomized, double-blinded, placebo-controlled, dose-ranging study evaluating the efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis
Zhang, Chunlei
Yan, Kexiang
Diao, Qingchun
Guo, Qing
Jin, Hongzhong
Yang, Sen
Chen, Xiang
Lei, Tiechi
Wu, Jianhua
Yu, Hong
Zheng, Min
Gao, Xinghua
Sinclair, Rodney
Zhu, Yi
Xu, Qian
Xu, Jinhua
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (01) : 95 - 102
[6] EFFICACY AND SAFETY OF IXEKIZUMAB IN A RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED, PHASE 3B CLINICAL TRIAL IN PATIENTS WITH MODERATE-TO-SEVERE GENITAL PSORIASIS
Ryan, C.
Menter, A.
Guenther, L.
Blauvelt, A.
Bissonnette, R.
Yang, F. E.
Bleakman, Potts A.
JOURNAL OF SEXUAL MEDICINE, 2018, 15 (02): : S6 - S7
[7] Efficacy and Safety of Ixekizumab in a Randomized, Double-Blinded, Placebo-Controlled, Phase 3b Clinical Trial in Patients with Moderate-to-Severe Genital Psoriasis
Ryan, Caitriona
Menter, Alan
Guenther, Lyn
Blauvelt, Andrew
Bissonnette, Robert
Yang, Fan Emily
Bleakman, Alison Potts
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2018, 16 : 13 - 14
[8] Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled, phase 3b clinical trial in patients with moderate-to-severe genital psoriasis
Ryan, C.
Menter, A.
Guenther, L.
Blauvelt, A.
Bissonnette, R.
Yang, F. E.
Bleakman, A. Potts
Burkhardt, N.
AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2018, 59 : 42 - 42
[9] Efficacy and safety of fumaric acid esters in young patients aged 10-17 years with moderate-to-severe plaque psoriasis: a randomized, double-blinded, placebo-controlled trial
Hamm, H.
Wilsmann-Theis, D.
Tsianakas, A.
Gambichler, T.
Taipale, K.
Lauterbach, J.
Freudensprung, U.
Makepeace, C.
BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (01) : 62 - 73
[10] Efficacy and safety of vunakizumab in moderate-to-severe chronic plaque psoriasis: A randomized, double-blind, placebo-controlled phase 3 trial
Yan, Kexiang
Li, Fuqiu
Bi, Xiaodong
Han, Ling
Zhang, Zhenghua
Chen, Rixin
Li, Yuye
Zhang, Litao
Wang, Xiaohua
Li, Linfeng
Lu, Jianyun
Xu, Ai'e
Yang, Sen
Lu, Yan
Sun, Jianfang
Li, Zhiming
Zhu, Xiaohong
Jiang, Meiying
Zhang, Siping
Wang, Wenqing
Li, Yanling
Meng, Zudong
Li, Hongyi
Mou, Kuanhou
Han, Xiuping
Li, Shanshan
Chen, Aijun
Li, Xin
Liu, Donghua
Zhang, Chunlei
Ji, Chao
Wang, Yu
Cheng, Hao
Cui, Xiaojing
Yao, Xiaoyan
Bai, Xiaoyan
Dong, Guangchao
Xu, Jinhua
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2025, 92 (01) : 92 - 99

← 1 2 3 4 5 →